MYD88 and diffuse large B-cell lymphoma: Although there is currently no clear correlation between MYD88 mutational profiles and ibrutinib response (Visco et al., 2020), several studies have shown clinical responses to ibrutinib treatment in some DLBCL patients with an MYD88L265P mutation (Deng et al., 2017; Soussain et al., 2019).